- Home
- PGEN vs GHI Comparison
PGEN vs GHI Comparison
Compare PGEN & GHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PGEN | GHI |
|---|---|---|
| Founded | 1998 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 173.3M |
| IPO Year | 2013 | 1998 |
Fundamental Metrics
Financial Performance| Metric | PGEN | GHI |
|---|---|---|
| Price | $4.17 | $5.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 3 |
| Target Price | $8.33 | ★ $10.50 |
| AVG Volume (30 Days) | ★ 2.9M | 60.6K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 22.93% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | ★ $230,981,000.00 | $85,389,766.00 |
| Revenue This Year | $1,115.92 | $273.95 |
| Revenue Next Year | $81.04 | N/A |
| P/E Ratio | ★ N/A | $527.50 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.28 | $4.71 |
| 52 Week High | $5.47 | $12.27 |
Technical Indicators
Market Signals| Indicator | PGEN | GHI |
|---|---|---|
| Relative Strength Index (RSI) | 51.20 | 47.05 |
| Support Level | $3.97 | $4.71 |
| Resistance Level | $4.40 | $5.52 |
| Average True Range (ATR) | 0.23 | 0.19 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 27.37 | 41.96 |
Price Performance
Historical ComparisonAbout PGEN Precigen Inc.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
About GHI Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.